Efficacy of Surgical Systems in Combination With Phacoemulsification: a Retrospective Analysis
Sponsored by Barnet Dulaney Perkins Eye Centers
About this study
Real-World efficacy of Hydrus Microstent with OMNI Surgical System in combination with Phacoemulsification: a retrospective analysis
The use of combination Phacoemulsification, OMNI Canaloplasty and Hydrus microstent successfully lowers IOP in ethnically-diverse patients with Open Angle Glaucoma
Where this study is enrolling
- I'm interested
Barnet Dulaney Perkins Eye Center
Mesa, Arizona
Who can participate
Inclusion criteria
- ✓Subjects with h/o CEIOL/OMNI/Hydrus (chosen based on subjects on more than 1 medication pre-operatively) with at least 3 years of follow up data
- ✓have Glaucoma
Exclusion criteria
- ✕Patients with angle closure glaucoma or secondary forms of glaucoma due to neovascularization of the angle, uveitic glaucoma, congenital glaucoma, or glaucoma due to congenital anomalies.
- ✕Patients with refractory CME or CME persisting 3 months or more post-operatively
- ✕Patients with incomplete IOP, medication logs or VF data within post-operative period
- ✕Prior incisional surgery or MIGS
Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.